Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
|Articles|October 10, 2005
Supplements and Featured Publications
- Managing Bipolar Disorder: Misdiagnosis and Quality of Life
- Volume 11
- Issue 9 Suppl
Participating Faculty
Advertisement
The American Journal of Managed Care
This supplement to includes information on how bipolar disorder affects quality of life and the impact of misdiagnosis. This program has been peer reviewed by experts in the field.
Faculty
Robert M. A. Hirschfeld, MD
Professor and Chair
University of Texas Medical Branch
Instructor of Psychiatry
Boston, Massachusetts
Lana A. Vornik, MSc
Department of Psychiatry and Behavioral Sciences
Galveston, Texas
Faculty Disclosure
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.
These participants report relationships with the following pharmaceutical companies:
Consultant/advisory board member to:
- Abbott Laboratories
- Bristol-Myers Squibb
- Forest Laboratories
- Janssen
- Organon
- Shire
- Wyeth-Ayerst
- Lana A. Vornik, MSc Consultant to: Janssen
Honoraria or consulting fees from:
- Bristol-Myers Squibb
- GlaxoSmithKline Pfizer
The American Journal of Managed Care,
Signed disclosures are on file at the offices of Jamesburg, New Jersey.
This supplement has been supported by funding from AstraZeneca Pharmaceuticals.
---
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Articles in this issue
almost 21 years ago
Misdiagnosis of Bipolar Disorderalmost 21 years ago
Bipolar Disorder: Quality of Life and the Impact of Atypical Antipsychoticsalmost 21 years ago
Managing Bipolar Disorder: Misdiagnosis and Quality of LifeAdvertisement
Related to this article
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Tavapadon for Parkinson Disease Approved by FDA
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5